Analyst: Biogen Idec Gains Are Done 24/7 Wall St. Pipeline: daclizumab, anti-LINGO, others could create long-term value. While we expect weakness on BG-12 launch, we think BIIB's pipeline will create significant long-term value. For investors with a 12-month+ horizon, we think BG-12-driven weakness ... |
